(Q28576424)

31 January 2017

title

Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate (English)

1 reference

31 January 2017

1 reference

1 reference

Fabien Forcheron

1

1 reference

31 January 2017

Pauline Abdallah

2

1 reference

31 January 2017

Alexandra Basset

3

1 reference

31 January 2017

Peggy del Carmine

4

1 reference

31 January 2017

Ghina Haffar

5

1 reference

31 January 2017

Michel Beylot

6

1 reference

31 January 2017

publication date

1 July 2009

1 reference

31 January 2017

1 reference

31 January 2017

volume

17

1 reference

31 January 2017

issue

7

1 reference

31 January 2017

page(s)

1381–1389

1 reference

Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease

31 January 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Carbohydrate responsive element-binding protein (ChREBP): a key regulator of glucose metabolism and fat storage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Nonalcoholic fatty liver disease and the metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Metformin reverses fatty liver disease in obese, leptin-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Comparison of the expression and activity of the lipogenic pathway in human and rat adipose tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Analysis of gene expression profiles in insulin-sensitive tissues from pre-diabetic and diabetic Zucker diabetic fatty rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Regulation of hepatic fatty acid oxidation and ketone body production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Living up to a name: the role of the VLDL receptor in lipid metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Turnover and splanchnic metabolism of free fatty acids and ketones in insulin-dependent diabetics at rest and in response to exercise

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Modulation of carbohydrate response element-binding protein gene expression in 3T3-L1 adipocytes and rat adipose tissue.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

PPARalpha activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Influence of Gemfibrozil and Clofibrate on Metabolism of Cholesterol and Plasma Triglycerides in Man

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

Regulation of lipogenic enzyme gene expression by nutrients and hormones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.661

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

1 reference

31 January 2017

1 reference